Previous studies reported that miR-330-3p was involved in the progression of several cancers, but the potential roles of miR-330-3p in ovarian cancer (OC) were unclear. In the current study, we aimed to explore the expression pattern and functions of miR-330-3p in OC. The expression level of miR-330-3p in OC tissues and cell lines was detected using RT-qPCR. The proliferation, migration and invasion of OC cells were detected using CCK-8 assay and transwell assay, respectively. Bioinformatics analysis and luciferase reporter assay were used to analyze the targeted binding site of miR-330-3p and RIPK4. The results showed that miR-330-3p was significantly downregulated in OC tissues and cell lines. Overexpression of miR-330-3p inhibited the proliferation, migration and invasion of OC cells. Mechanistically, a dual-luciferase reported assay showed that RIPK4 is a target gene of miR-330-3p. Furthermore, rescue experiments revealed that miR-330-3p suppressed the proliferation, migration and invasion of OC cells by targeting RIPK4. In summary, our findings indicated that miR-330-3p suppressed the progression of OC by targeting RIPK4. Our results indicated that miR-330-3p/RIPK4 axis might act as a novel therapeutic target for OC treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291835 | PMC |
| http://dx.doi.org/10.1080/21655979.2021.1871817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma genome-wide mendelian randomization identifies potentially causal genes in idiopathic pulmonary fibrosis.
Respir Res
October 2024
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277#, Yanta West Road, Xi'an, Shaanxi Province, 710061, China.
Background: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease with a very poor prognosis. Existing drugs for the treatment of IPF are still insufficient. Therefore, there is still a need to explore new drug targets for preventing and treating IPF.
View Article and Find Full Text PDFSystematic Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets for Functional Outcome After Ischemic Stroke.
J Am Heart Assoc
August 2024
Department of Neurology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Article Synopsis
- * The study utilized genetic data to analyze over 2600 druggable genes, identifying 16 genes linked to improved functional outcomes, with further support from analysis techniques like Mendelian randomization and colocalization.
- * Four key candidate genes were pinpointed as potential therapeutic targets to enhance recovery after ischemic stroke, although more research is needed to understand their mechanisms and ensure safety.
Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
Oncogene
June 2024
Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Article Synopsis
- Somatic copy number alterations (SCNAs), especially arm-level SCNAs, are linked to cancer growth and resistance to treatment, but their role in triple-negative breast cancer (TNBC) is not well understood.
- In this study, researchers found that certain arm-level SCNAs, like gains at 21q and 7p, are connected to poorer survival rates in TNBC patients, with the gene RIPK4 on 21q being particularly significant.
- Targeting RIPK4 in experiments showed promise, as it reduced tumor growth and improved survival by enhancing immune cell infiltration, suggesting RIPK4 could be a key factor in TNBC progression and its ability to spread.
GSK3β and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
Oncogene
June 2024
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China.
Receptor-interacting protein kinase 4 (RIPK4) is increasingly recognized as a pivotal player in ovarian cancer, promoting tumorigenesis and disease progression. Despite its significance, the posttranslational modifications dictating RIPK4 stability in ovarian cancer remain largely uncharted. In this study, we first established that RIPK4 levels are markedly higher in metastatic than in primary ovarian cancer tissues through single-cell sequencing.
View Article and Find Full Text PDFThe involvement of RIPK4 in TNF-α-stimulated IL-6 and IL-8 production by melanoma cells.
J Cancer Res Clin Oncol
April 2024
Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Kraków, Poland.
Purpose: The receptor-interacting protein kinase (RIPK4) has an oncogenic function in melanoma, regulates NF-κB and Wnt/β-catenin pathways, and is sensitive to the BRAF inhibitors: vemurafenib and dabrafenib which lead to its decreased level. As its role in melanoma remains not fully understood, we examined the effects of its downregulation on the transcriptomic profile of melanoma.
Methods: Applying RNA-seq, we revealed global alterations in the transcriptome of WM266.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!